National Institute of
Environmental Health Sciences
Division of Translational Toxicology



Animal-Free Innovation: Drivers and Vision International Perspective

Helena Hogberg, PhD

National Interagency Center for the Evaluation of Alternative Toxicological Methods

National Institute of Environmental Health Sciences
Division of Translational Toxicology

NICEATM and ICCVAM

- National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (**NICEATM**), supporting the Interagency Coordinating Committee for the Validation of Alternative Methods (**ICCVAM**)
- ICCVAM Authorization Act of 2000: To establish, wherever feasible, guidelines, recommendations, and regulations that promote the regulatory acceptance of new and revised toxicological tests that protect human and animal health and the environment while reducing, refining, or replacing (**3Rs**) animal tests and ensuring human safety and product effectiveness.

7 Regulatory Agencies

Consumer Product Safety Commission
Department of Agriculture
Department of the Interior
Department of Transportation
Environmental Protection Agency
Food and Drug Administration
Occupational Safety and Health Administration

10 Research Agencies

Agency for Toxic Substances and Disease Registry
National Institute for Occupational Safety and Health
National Cancer Institute
National Institute of Environmental Health Sciences
National Library of Medicine
National Institutes of Health
Department of Defense
Department of Energy
National Institute of Standards and Technology
Veterans Affairs Office of Research and Development

*Other participants include: NCATS, Tox21 Representatives

More information: https://ntp.niehs.nih.gov/go/iccvam

"Advances in science and technology have not been effectively leveraged to predict adverse human health effects"



Help end-users guide the development of the new methods

Use efficient and flexible approaches to establish confidence in new methods

Encourage the adoption of new methods by federal Agencies and regulated industries

"Advances in science and technology have not been effectively leveraged to predict adverse human health effects"



Help end-users [illegible] development of the new m[illegible]

Use eff[illegible]nt and [illegible]e ap[illegible]aches to establis[illegible]nce [illegible]new [illegible]thods

Encourage t[illegible] new methods by federal Agencies and regulated industries

ICCVAM: Validation Workgroup

Updating ICCVAM Guidance on Validation

ICCVAM Sponsor Agencies:
CPSC, FDA/CFSAN

Participating Agencies:
EPA/OPP, EPA/ORD, ATSDR, VA ORD, DOD, NIST, OSHA, NIEHS, NIH, FDA/CDER,/CTP,/OCS,/CDRH



NIH PUBLICATION NO: 97-3981

National Institute of Environmental Health Sciences
Research Triangle Park, North Carolina 27709

National Institutes of Health
U.S. Public Health Service
Department of Health and Human Services

March 1997

New Guidance from ICCVAM

- Underlying principles from OECD 34 remain the same in this new Guidance.
- Introduce the “context of use” terminology
- New guidance will emphasize that processes used to establish confidence should be flexible and adaptable.
- Emphasize the need for communication because regulatory needs may vary across the federal agencies

Updated ICCVAM Validation Guidance: Coming Soon!



Regulatory Focused Case Study on Bioactivity as a Point-of-Departure

APCRA
ACCELERATING THE PACE OF CHEMICAL RISK ASSESSMENT



OXFORD | SOT Society of Toxicology
academic.oup.com/toxsci

TOXICOLOGICAL SCIENCES, 2019, 1–24

doi: 10.1093/toxsci/kfz201
Advance Access Publication Date: September 18, 2019
Research Article

Utility of *In Vitro* Bioactivity as a Lower Bound Estimate of *In Vivo* Adverse Effect Levels and in Risk-Based Prioritization

Katie Paul Friedman ,*,1 Matthew Gagne,† Lit-Hsin Loo,‡ Panagiotis Karamertzanis,§ Tatiana Netzeva,§ Tomasz Sobanski,§ Jill A. Franzosa,¶ Ann M. Richard,* Ryan R. Lougee,*,|| Andrea Gissi,§ Jia-Ying Joey Lee,‡ Michelle Angrish,|| Jean Lou Dorne,|| Stiven Foster,# Kathleen Raffaele,# Tina Bahadori,|| Maureen R. Gwinn,* Jason Lambert,* Maurice Whelan,** Mike Rasenberg,§ Tara Barton-Maclaren,† and Russell S. Thomas *

*National Center for Computational Toxicology, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, 27711; †Healthy Environments and Consumer Safety Branch, Health Canada, Government of Canada, Ottawa, Ontario, Canada, K1A0K9; ‡Innovations in Food and Chemical Safety Programme and Bioinformatics Institute, Agency for Science, Technology and Research, Singapore, 138671, Singapore; §Computational Assessment Unit, European Chemicals Agency, European Chemicals Agency Annankatu 18, P.O. Box 400, FI-00121 Helsinki, Uusimaa, Finland; ¶National Health and Environmental Effects Research Laboratory, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, 27711; ||Oak Ridge Institute for Science and Education, U.S. Department of Energy, Oak Ridge, TN 37831, USA; ||National Center for Environmental Assessment, Office of Research and Development, US Environmental Protection Agency, Washington, DC, 20004 and Research Triangle Park, NC 27711; ||Scientific Committee and Emerging Risks Unit Department of Risk Assessment and Scientific Assistance, Via Carlo Magno 1A, 43126 Parma, Italy; #Office of Land and Emergency Management, U.S. Environmental Protection Agency, Washington, DC, 20004; and ~European Commission, Joint Research Centre (JRC), Via Enrico Fermi, 2749, I - 21027 Ispra, Italy

*To whom correspondence should be addressed at 109 T.W. Alexander Drive, Mail Drop D143-02, Research Triangle Park, NC 27711. Fax: (919) 541-1194. E-mail: paul-friedman.katie@epa.gov.

Disclaimer: The United States Environmental Protection Agency (U.S. EPA) through its Office of Research and Development has subjected this article to Agency administrative review and approved it for publication. Mention of trade names or commercial products does not constitute endorsement for use. The views expressed in this article are those of the authors and do not necessarily represent the views or policies of A*STAR, U.S. EPA, EFSA, ECHA, Health Canada, or the JRC.

ABSTRACT

Use of high-throughput, *in vitro* bioactivity data in setting a point-of-departure (POD) has the potential to accelerate the pace of human health safety evaluation by informing screening-level assessments. The primary objective of this work was to compare PODs based on high-throughput predictions of bioactivity, exposure predictions, and traditional hazard information for 448 chemicals. PODs derived from new approach methodologies (NAMs) were obtained for this comparison using the 50th ($POD_{NAM,50}$) and the 95th ($POD_{NAM,95}$) percentile credible interval estimates for the steady-state plasma

Published by Oxford University Press on behalf of the Society of Toxicology 2019.



For ~89% of the chemicals, POD_{NAM} was conservative.

(~100-fold on average), but less conservative than a TTC

Chemicals where POD_{NAM} was not conservative enriched in OPs/carbamates

Courtesy of Rusty Thomas

Reference Data Variability

Data-driven Confidence Intervals for Model Evaluation/Predictions



OPERA
OPEn (q)saR App

Analyzing sources of variability in acute oral toxicity data & applying 95% confidence interval to predictions

	0	5	50	300	500	2000	5000 mg/kg
VT	0	0	1	1	1	1	1
NT	1	1	1	1	1	0	0
EPA	0	0	1	1	0	0	0
GHS	0	0	1	0	0	0	0
LD50	0	0	1 (160)	(-0.3) 1 (316)	(+0.3) 1 (613)	0	0
WoE	**1**	**1**	**5**	**4**	**3**	**1**	**1**

	Very Toxic		Non-Toxic		EPA		GHS	
	Train	Eval	Train	Eval	Train	Eval	Train	Eval
Sensitivity	0.87	0.70	0.88	0.67	0.81	0.62	0.80	0.58
Specificity	0.99	0.97	0.97	0.90	0.92	0.86	0.95	0.90
Balanced Accuracy	0.93	0.84	0.92	0.78	0.87	0.74	0.88	0.74
***In vivo* Balanced Accuracy**	0.81		0.89		0.82		0.79	

	LD50 values		LD50 values
	Train	Eval	***In Vivo***
R2	0.85	0.65	0.80
RMSE	0.30	0.49	0.42

CATMoS QSAR predictions perform just as well as replicate *in vivo* data at predicting oral acute toxicity outcome

Karmaus et al. Toxicol Sci. 2022; Mansouri et al. EHP 2021

Human Relevance

Prior GHS category	1	2A	2B	NC
1 (serious eye damage)	73%	16%	0%	10%
2A (irritant)	4%	33%	4%	59%
2B (mild irritant)	0%	4%	16%	80%
NC (non-irritant)	1%	4%	2%	94%

Adapted from Luechtefeld et al., ALTEX 33(2), 2016.

Consider strengths and limitations of all available methods with respect to:

- their relevance to human ocular anatomy
- the mechanisms of eye irritation/corrosion in humans

Clippinger et al. 2021 Cut Ocu Tox

Assessing approaches for eye corrosion/irritation potential

- The rabbit test should not be used as a reference method to demonstrate the validity of *in vitro/ex vivo* assays
- *In vitro/ex vivo* methods are as or more reliable and relevant than the rabbit test



Image modified from Scott, et al., 2010

AOP-Anchoring





DA/Method	Information Sources	Capability (Hazard and/or Potency)	Hazard Performance vs. LLNA N~168	Hazard Performance vs. Human N~63	GHS Potency Performance vs. LLNA (Accuracy)	GHS Potency Performance vs. Human (Accuracy)
2o3 DA	DPRA, KeratinoSens™, h-CLAT	Hazard	84% BA, 82% Sens, 85% Spec	88% BA, 89% Sens, 88% Spec	-	-
ITSv1 DA	DPRA, h-CLAT, DEREK Nexus v6.1.0	Hazard, Potency (GHS)	81% BA, 92% Sens, 70% Spec	69% BA, 93% Sens, 44% Spec	70% NC, 71% 1B, 74% 1A	44% NC, 77% 1B, 65% 1A
ITSv2 DA	DPRA, h-CLAT, OECD QSAR Toolbox v4.5	Hazard, Potency (GHS)	80% BA, 93% Sens, 67% Spec	69% BA, 94% Sens, 44% Spec	67% NC, 72% 1B, 72% 1A	44% NC, 80% 1B, 67% 1A
LLNA (provided for comparison)	*in vivo*	Hazard, Potency	-	58% BA, 94% Sens, 22% Spec	-	25% NC, 74% 1B, 56% 1A

Lessons (Continuously) Learned & Being Applied

- Roadmap 101: Engagement with regulatory stakeholders



- Fit for purpose, performance-based evaluations

- Opportunity for tailored assessments, where data requirements are driven by use cases



- Communication is key

- There are multiple NAMs that are ready for use now!

National Institute of Environmental Health Sciences
Division of Translational Toxicology

The NICEATM Group



Integrated Chemical Environment

Report for 2020-2021 is out now!

https://ntp.niehs.nih.gov/go/2021iccvamreport

Subscribe to NICEATM News email list
https://ntp.niehs.nih.gov/go/niceatm